ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy.
William John Gradishar
No relevant relationships to disclose
Zsuzsanna Kahan
No relevant relationships to disclose
Janice Tsang
No relevant relationships to disclose
Constanta Timcheva
No relevant relationships to disclose
Sergei Tjulandin
Honoraria - AstraZeneca; Roche
Fatima Cardoso
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Ruta Grigiene
No relevant relationships to disclose
Hiroji Iwata
No relevant relationships to disclose
Maccon Keane
No relevant relationships to disclose
Kristina Luebbe
No relevant relationships to disclose
Zora Neskovic-Konstantinovic
No relevant relationships to disclose
Sergio D. Simon
No relevant relationships to disclose
Salomon Stemmer
No relevant relationships to disclose
Damir Vrbanec
No relevant relationships to disclose
Tammy Arbani
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Allison M. Florance
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Yingjie Huang
Employment or Leadership Position - GlaxoSmithKline
Meggan Leigh
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Susan Wroblewski
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Stephen R. D. Johnston
Research Funding - GlaxoSmithKline